Cargando…
Rapid and Sustained Eyelid Elevation in Acquired Blepharoptosis with Oxymetazoline 0.1%: Randomized Phase 3 Trial Results
PURPOSE: Oxymetazoline 0.1% is a novel ophthalmic agent for the treatment of acquired blepharoptosis in adults that has been shown to improve upper eyelid elevation and superior visual field deficits. This analysis characterized the rapid onset of upper eyelid elevation with once-daily oxymetazoline...
Autores principales: | Bacharach, Jason, Wirta, David L, Smyth-Medina, Robert, Korenfeld, Michael S, Kannarr, Shane R, Foster, Shane, J Jaros, Mark, Slonim, Charles B |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8240850/ https://www.ncbi.nlm.nih.gov/pubmed/34211263 http://dx.doi.org/10.2147/OPTH.S306155 |
Ejemplares similares
-
Safety of Once-Daily Oxymetazoline HCl Ophthalmic Solution, 0.1% in Patients with Acquired Blepharoptosis: Results from Four Randomized, Double-Masked Clinical Trials
por: Wirta, David L, et al.
Publicado: (2021) -
Association of Oxymetazoline Hydrochloride, 0.1%, Solution Administration With Visual Field in Acquired Ptosis: A Pooled Analysis of 2 Randomized Clinical Trials
por: Slonim, Charles B., et al.
Publicado: (2020) -
A review of acquired blepharoptosis: prevalence, diagnosis, and current treatment options
por: Bacharach, Jason, et al.
Publicado: (2021) -
Frontalis Suspension Surgery in Upper Eyelid Blepharoptosis
por: Takahashi, Yasuhiro, et al.
Publicado: (2010) -
Eyelid Retraction in Isolated Unilateral Congenital Blepharoptosis
por: Salman, Michael S., et al.
Publicado: (2017)